Overzicht lopende oncologische studies​

Amgen-20140299

A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases.

  • Atezolizumab (anti-PD-L1) IV in combinatie met TVEC injecties in levermetastasen

MASTERKEY-318

A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab.

  • TVEC injecties in HCC met of zonder Pembrolizumab (anti-PD-1) IV

M15-891

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181, as Monotherapy and in Combination with Another Anti-Cancer Therapy in Subjects with Advanced Solid Tumors. (M15-891).

  • ABBV-181 (nieuw anti-PD1 antilichaam) in monotherapie of in combinatie met ofwel Rova-T ofwel Venetoclax

ACT15377

A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with atezolizumab or isatuximab alone in patients with advanced malignancies.

  • Atezolizumab (anti-PD-L1) in combinatie met isatuximab (anti-CD38)

BP40234

An open-label, multicenter, phase II study to evaluate the therapeutic activity of RO6874281, an immunocytokine, consisting of interleukin-2 variant (IL-2v) targeting fibroblast activation protein-A (FAP), in combination with atezolizumab (anti-PD-L1), administered intravenously, in participants with advanced and/or metastatic solid tumors.

  • Atezolizumab (anti-PD-L1) in combinatie met RO6874281 (FAP-targeted IL-2v)

CA044-001

Phase I/II Study of BMS-986310 Administered Alone and in Combination with Nivolumab in Participants with Advanced Solid Tumors.

  • Nivolumab (anti-PD-1) in combinatie met BMS-986310 (orale prostaglandine-receptor EP4 antagonist)

BI1367.1

An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit. 

  • Monotherapie met BI 894999, een orale BET-inhibitor

B9991033 

A Phase 1B/2 study to evaluate safety and clinical activity of avelumab in combination with binimetinib with or without talazoparib in patients with locally advanced or metastatic RAS-mutant solid tumors.
  • Binimetinib (MEK 1/2 inhibitor) in combinatie met talazoparib (PARP inhibitor), al dan niet in combinatie met avelumab (anti-PD-L1) 

XL184-021

A Phase 1b Dose-Escalation Study of Cabozantinib Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors.

  • Atezolizumab (anti-PD-L1) in combinatie met Cabozantinib (tyrosine kinase inhibitor) of - in bepaalde cohorten - Cabozantinib monotherapie.

IO-001

Phase I/Ib First-in-Human study of EOS100850 in patients with advanced solid tumors.

  • Monotherapie met EOS100850, een orale adenosine A2a receptor antagonist

CA027-002

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers.

  • Nivolumab (anti-PD-1) in combinatie met BMS-986253, een anti-IL8 monoclonaal antilichaam

J1E-MC-JZEA

A Phase 1 Study of LY3434172, a Bispecific Antibody Monotherapy in Advanced Solid Tumors

  • Bispecifiek antilichaam gericht tegen zowel PD-1 als PD-L1.

AMG20180101

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager AMG 160 in subjects with metastatic castration-resistant prostate cancer.

  • AMG160 (PSMA-targeted BiTE) in monotherapie, of in combinatie met pembrolizumab (anti-PD-1)

RAGNAR

A phase 2 study of erdafitinib in subjects with advanced solid tumors and FGFR gene alterations.

  • Erdafitinib (FGFR inhibitor) in monotherapie

SURPASS

A phase 1 dose escalation study to assess safety and efficacy of ADP-A2M4CD8 in HLA-A2+ subjects with MAGE-A4 positive tumors.

  • MAGE-A4 gerichte CAR-T cellen.